Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 2Pheochromocytoma 1Ganglioneuroblastoma 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 7dinutuximab 6Topotecan 5Isotretinoin 5Doxorubicin 5Biopsy 5sargramostim 4Vincristine 4Stem Cell Transplantation 4Specimen Handling 4Radiation 4Platinum 4Melphalan 4Colony-Stimulating Factors 4Cisplatin 4Carboplatin 41,2-diaminocyclohexaneplatinum II citrate 4Thiotepa 3Temozolomide 3Irinotecan 3Etoposide 3Congresses as Topic 33-Iodobenzylguanidine 3etoposide phosphate 2Razoxane 2Dexrazoxane 2Busulfan 2lorlatinib 1iberdomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × 3-fluorobenzylguanidine × 1 year × Clear all
NCT06858501 2026-03-19

Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

Children's Oncology Group

Phase 2 Not yet recruiting
84 enrolled
CNS

Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡